Avanos Medical, Inc.

NYSE:AVNS

Medical - Devices

Healthcare
$24.99 +0.22%

+$0.06 today

Market cap
$1.17B
Beta
1.57
P/E (TTM)
-16.7
EPS (TTM)
-$1.50
52W Low $9.30High $25.49

Volume 0.43M

Average 1.49M

AVNS Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Avanos Medical, Inc.NYSE: AVNS

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $5.2M fell 3.7% year over year, ahead of the -6.9% change in trailing-twelve-month research & development. Sequentially, it fell 14.8% from the prior quarter. Over 3 fiscal years it compounded at -8.9% a year.

Context

  • Research & development amounted to 3.3% of revenue in FY2025, down 0.5 pp from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -3.7% holds above the trailing-twelve-month pace of -6.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.2M-14.8% QoQ
Last fiscal yearDec 2025
$23.1M-11.8% YoY
LTMMar 2026
$22.9M-6.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.7%——
1 year-11.8%——
3-year CAGR-8.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
23.1M USD
Year-over-year change
-11.8%
4-year CAGR
-8.0%

Research & Development vs competitors

How AVNS compares with its peers on the latest reported figures

  • AVNS's LTM Mar 2026 research & development of $22.9M is the 6th highest of the 11 companies compared; the peer median is $29.41M.
  • Its year-over-year change of -6.9% is the 6th highest of 10, against a peer median of +0.1%.
  • Research & development amounts to 3.2% of revenue for AVNS, versus a peer median of 24.1%.
AVNS Competitors Peer median
Research & Development for AVNS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BCYCBicycle Therapeutics plcLTM Mar 2026$230.13M +16.7%+43.3%362.4%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$219.98M +42.7%+34.6%249.3%
VREXVarex Imaging CorporationLTM Apr 2026$89.5M +0.1%+5.8%10.4%
PACBPacific Biosciences of California, Inc.LTM Mar 2026$87.86M -27.1%-20.4%54.9%
CTKBCytek Biosciences, Inc.LTM Mar 2026$36.35M -7.6%+1.5%17.8%
AVNSAvanos Medical, Inc.LTM Mar 2026$22.9M -6.9%-8.9%3.2%
LABStandard BioTools Inc.LTM Mar 2026$22.48M -43.6%-11.4%26.1%
CBLLCeriBell, Inc.LTM Mar 2026$21.06M +43.4%+38.3%22.2%
CLPTClearPoint Neuro, Inc.LTM Mar 2026$15.04M +14.4%+8.5%37.0%
BVSBioventus Inc.LTM Mar 2026$11.57M -19.0%-20.2%2.0%
CYHCommunity Health Systems, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding AVNS) $29.41M+0.1%+5.8%24.1%

Competitors are the stored peer set for AVNS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue744.6M684.1M673.3M687.8M701.2M
Cost of Revenue364.7M289.9M293.6M306.5M352.2M
Gross Profit379.9M394.2M379.7M381.3M349M
Gross Margin51.0%57.6%56.4%55.4%49.8%
Research & Development32.3M30.6M27.2M26.2M23.1M
Selling, General & Admin260.8M323.1M287.5M315.1M218.3M
Operating Expenses293.1M352.3M314.7M341.3M410.6M
Depreciation & Amortization38.3M41.1M43.5M45.5M29M
EBITDA48.9M77.8M50.6M(345.6M)(33.2M)
EBITDA Margin6.6%11.4%7.5%-50.2%-4.7%
Operating Income86.8M41.9M65M40M(61.6M)
Operating Margin11.7%6.1%9.7%5.8%-8.8%
Interest Income200K1.2M2.9M5.1M3.2M
Interest Expense3.3M10M15M12.2M4M
Other Income / Expenses(79.5M)(15.2M)(72.9M)(443.3M)(4.6M)
Income Before Tax7.3M26.7M(7.9M)(403.3M)(66.2M)
Pre-Tax Margin1.0%3.9%-1.2%-58.6%-9.4%
Income Tax Expense1M5.2M2M(17M)1.7M
Net Income6.3M50.5M(61.8M)(392.1M)(67.9M)
Net Margin0.8%7.4%-9.2%-57.0%-9.7%
EPS (Basic)0.131.08(1.33)(8.53)(1.46)
EPS (Diluted)0.131.07(1.33)(8.53)(1.46)
Weighted Avg Shares48.1M46.9M46.6M46M46.4M
Weighted Avg Shares (Diluted)48.6M47.3M46.6M46M46.4M

Avanos Medical, Inc.

NYSE:AVNS

Intrinsic Alpha fair value

Locked

Current Price

$24.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.